Medications given once daily may increase compliance for treatment of hypertension, if the drugs have a prolonged duration Pf action. The time-effect profiles for antihypertensive ckugs may not depend entirely on pharmacokinetic measurements (plasma levels). Thus, trough/peak effects on blood pressure should be measured. It has been suggested that trough/peak ratios be greater than 50% for optimal 24-h control of pressure. Because very little information is available for many angiotensin converting enzyme (ACE) inhibitors and calcium antagonists concerning their trough/peak ratios and awaiting prospective comparative trials with adequate methodology, we have analyzed the duration of action of blood pressure lowering during longterm therapy with commercially available ACE inhibitors and calcium antagonists in published studies that used ambulatory blood pressure monitoring. Published studies were searched in scientific databases using relevant key words. Twenty-four ACE inhibitor and 34 calcium antagonist studies with comparable methodologies were selected. The mean trough/ peak ratios were computed after reconstruction of the curve of the magnitude of blood pressure changes against time. The results showed that once daily administration of ACE inhibitors produced on average ratios higher than 50% with fosinopril (64%), ramipril (50% to 63%), and trandolapril (50% to 100%). Other studied ACE inhibitors produced ratios on average equal to [enalapril (40% to 64%), cilazapril (10% to 80%), lisinopril (30% to 70%)1 or significantly lower than 50% [captopril (25%), benazepril (40%), perindopril (35%), quinapril (10% to 40%), and moexipril (OYO to 9Y0)1. As for once daily calcium antagonists, amlodipine (50Y0 to 100?L), lacidipine (40% to 100%), nifedipine Coat-Core (50% to 69% ), nifedipine gastrointestinal therapeutic system (GITS) (60Y0 to 9494), as well as various "slow release" formulations of diltiazem (209'oto 80% ) and verapamil (45% to 100%) had on average ratios higher than 50?40whereas felodipine ER (30% to 45%), various slow release formulations of isradipine (10% to 80%), and nitrendipine (1OYO to 8070) had ratios lower than 50%. Although this retrospective literature analysis may have some theoretical limitations, it suggests that not all once daily ACE inhibitors and calcium antagonists cause trough/peak ratio superior to 50?Z0. This may have important clinical implications. Am J Hypertens 1996; 9:633-643.
P harmacokinetic studies do not always provide adequate and simple methods that are capable of predicting reliably the time-effect profile for antihypertensive agents. One way to describe the profile of the effects of an antihypertensive agent on blood pressure (BP) throughout 24 h and during an interdosing interval is to characterize the trough and the peak effects of this agent.
Trough effect is the decrease in BP observed at the end of the interdosing interval, immediately before administration of the next dose. Because once daily drugs traditionally are administered in the morning, trough effects usually occur at that time of day when the BP rises sharply during the arousal process when the risk of cardiovascular events is highest. Thus a "usefuI" antihypertensive effect consists of a meaningful control of BP at trough.
Peak effect is the maximum reduction in BP after administration of a drug. It may, but need not, correspond to the time (T~,X) at which the drug's plasma concentration is at its highest level (C~,X). In general, peak effect occurs relatively early during the interposing interval, usually <8 h after drug intake. When pronounced, peak effect may be associated with several side effects.
Although the trough effect can be enhanced by increasing the size of the dose, this can create a danger of an excessive peak effect with related side effects and early hypotensive response. For smoothness of treatment effects, it has been suggested that once-aday antihypertensive agents have trough/peak ratios for effects on blood pressure > 50%.1 Indeed, contrary to the trough effect, most frequently the trough/peak ratio cannot be increased simply by increasing the administered dosage. For example, in a clinical doseranging study with benazepril, it appeared that, although the trough effect was dose related, the trough /peak ratio remained below 407. over a wide range of dosages (5 to 40 mg) administered once daily.z Because very little information on the time-activity profile is available for many agents and it is awaiting prospective comparative trials with adequate methodology, we decided to calculate the trough/peak ratios from a retrospective analysis of published studies with the increasingly popular and most prescribed antihypertensive agents: ie, agents belonging to the class of angiotensin converting enzyme (ACE) inhibitors and the class of calcium antagonists.
METHODS
All published studies assessing the antihypertensive efficacy of commercially available ACE inhibitors and calcium antagonists with ambulatory blood pressure monitoring (ABPM) were reviewed, to evaluate the duration of activity of these drugs. We selected articles on Medline (1986 Medline ( to 1993 and Excerpta Medica (1988 to 1994) databases, using one or more of the following key words: blood pressure monitoring, blood pressure measurement (method), circadian rhythm, ambulatory blood pressure, 24-hour(s) ambulatory blood pressure monitoring, ambulatory monitoring, ACE inhibitors, benazepril, captopril, cilazapril, enalapril, fosinopril, Iisinopril, perindopril, quinapril, ramipril, and trandolapril as well as calcium antagonists, amlodipine, diltiazem, felodipine, isradipine, Iacidipine, nifedipine, nitrendipine, and verapamil. From these, we selected studies with the following criteria: q patients with mild or moderate hypertension, untreated or with at least 2 weeks washout period from any previous antihypertensive drug, at least 2 weeks placebo run-in period, monotherapy administered, once a day, for at least 2 weeks, 24-h ABPM both pre-and posttreatment, and hourly mean values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) available numerically or graphically.
each study we calculated and reconstructed the curve of the magnitude of DBP changes against time by subtracting values after active treatment from values obtained during the placebo washout period. This curve was subsequently smoothed using a polynomial regression best fit procedure (Figure 1 ). Calculations for SBP were also performed but are not reported in this article, as they produced essentially the same results as calculations relating to DBP, The trough /peak ratio was calculated. The trough effect was that measured 24 h postdose and the peak effect was the maximum reduction in BP during the 8 h postdose. Table 1 summarizes the results of the database search with the numbers of relevant clinical studies for each agent and the number of studies excluded for specific predefine selection criteria. Study designs are summarized in Tables 2 and 3 . Results are summarized in Tables 4 through 7 .
RESULTS

DISCUSSION
The data we have gathered from all available published studies suggests that not all commercially available once-a-day ACE inhibitors and calcium antagonists comply with the FDA recommendation of a trough /peak ratio superior to 50'%.1For example, in the studies analyzed, benazepril, perindopril, and quinapril as well as felodipine SR, isradipine SR, and nitrendipine had trough/peak ratios below 50Y0with once daily administration.
Previous reports have shown that among commercially available and extensively used antihypertensive agents there may be some variations in duration of action. Some once daily agents have temporarily reduced efficacy during the early morning hours. This is the case with the class of /3-blockers.3For example, Graettinger et a13showed that, although equieffective to once daily lisinopril during daytime, once daily 50 mg atenolol lost some of its efficacy during the final 4 h preceding the next day's dose. Once daily acebutolol, but not once daily atenolol, achieved trough/ peak ratios higher than 50% in a study conducted by Neutel et al.4 Other reports indicated that once daily slow-release felodipine could not achieve a consistent around the clock BP lowering.5 Obviously, the status of many drugs given once a day, with regard to trough /peak ratio, remains uncertain.
Interestingly, Graettinger et a13 demonstrated that the temporary loss of efficacy of~-blockers may not be related to an inadequate duration of pharmacologic action, for antihypertensive efficacy was restored again by midmorning even in the absence of additional drug dosing. This suggests that additional specific pharmacologic properties may be required for optimal coverage of the early morning BP rise. Thus, in some cases, the so-called trough effect, which happens to occur during the early morning simply because administration time is usually between 7 and 10 AM, may be determined by physiopathologic and pharmacodynamic factors other than the duration of antihypertensive action. In other respects, dosing time may also influence the time-effect profile. Palatini et alG have shown that the evening administration of once daily quinapril, a short acting ACE inhibitor, gave a more favorable antihypertensive profile than the morning administration of the same dose. Duration of action was longer and consequently the calculated trough/peak ratio changed from below 50% to above 50Y0,This may have several explanations, including a possible change in the pharmacokinetic profile with a delayed absorption and clearance after the evening dosing, as well as alternative pharmacodynamic effects, such as sympatholytic activity that may be predominant during the daytime after morning dosing. In contrast, in studies also comparing morning dosing, trough /peak ratios of isradipine7 and of nitrendipine8 tended to be greater after the morning administration, which may need alternative explanations. However, most frequently, failure to achieve adequate trough /peak ratios is related to short-acting agents used at an inappropriately long interdosing (36) Fariello (37) Hwang (38) Porcellati (39) Celis (40) Christensen (41) Diemont (42) Fogari (7)* Lacourciere (43) Lohmann (44) Waeber (45) Palatini (6, 46) Zito (47) Rizzoni (48) Zanchetti (49) Asmar ( 3  3  2  2  2  2  2  2  3  2  2  2  2  2 interval and at relatively high doses aimed to achieve a "useful" BP decrease at trough. Actually, this is an expected drawback of the systematic quest for the once daily regimen that is considered as the "gold standard" for antihypertensive therapy. Measurements of the Clinical Duration of Action Only preliminary information may be gained through small early phase II dose-finding trials with single or several doses of the drug, usually in a small number of confined patients who are followed for at least 24 h. The major limitation of this approach is that results may not be representative of a normal hypertensive population with normal daily life and environment. Ambulatory blood pressure monitoring is a useful alter- (70) Gourlay (64) Graettinger (3) Herpin (71) Mann (60) Whelton (72) Whelton (68) Zachariah ( native for comparing the efficacy and duration of action of differing antihypertensive agents and enables peak and trough drug effects to be quantified. Unlike studies based on conventional office BP measurements, evaluation of antihypertensive therapy using ABPM techniques does not show placebo effects.9'10 The reproducibility of the 24-h BP levels has been verified in studies using either intraarterial or noninvasive monitoring.ll'lz The actual circadian pattern of the BP, including the differences between daytime and nighttime values, appears to be highly reproducible during ABPM periods separated by several weeks.lzMancia et a113have stated several limitations of ABPM, some of which may apply to the use of this method for assessing the time-effect profile of antihypertensive agents. 170rinstance, reproducibility for hourly BP averages maybe poor between the placebo and active treatment periods when patients' activity is not controlled. In addition, artifactual and imprecise readings may confound determination of peak and trough effects. However, we believe that many of these shortcomings maybe avoided by careful design and statistical interpretation of the data. Interpretation will not be biased when mean data is used to make calculations of the trough/peak ratio. "Between hours" individual BP reproducibility maybe enhanced by monitoring BP in conditions of semicontrolled activities.14Smoothing procedures may remove artifactual readings.15The advantages of ABPM for studying the time-effect profile, duration of action, as well as trough /peak ratios of antihypertensive agents seem to be superior to its technical limitations. The main advantage is allowing studies to be performed on patients (7) Lacourci&e (43) Lohmann (44) Waeber (45) Palatini (6, 46) Zito (47) Rizzoni (48) Zanchetti (49) Asmar (50) Fogari (51) Grandinetti (28) Lohmann (44) Meilhac (8) Mengden (52) Waeber (35) Dupont (53) Kelly (54) Massie (55) Whelton (56) Verapamil Carr (57) NOVO (58 70  50  50  65  50  55  100  40  30  45  40  <lo  60  35  35  80  45  20  40  80  40  >100  50  69  60  94  70  <lo  60  50  80  65  20  25  20  80  50  50  60  50  50  >100  >100  45 undergoing their normal daily activities, which is a more pragmatic approach than early phase II studies performed in confined patients and in the artificial setting of a research unit. Despite being the only one that has been formally validated, the latter method, during phase II trials, should not stand alone as the basis for a decision about the appropriate interdosing interval for a drug. Evaluative approaches using ABPM are specifically encouraged by the US Food and Drug Administration (FDA).1
Study Limitations Literature analyses do not substitute for well-designed comparative clinical trials; however, the lack of such trials necessitates the drawing of conclusions from this literature analysis. Many biases may be introduced by retrospective analyses of data from studies of different designs, even though, by using strict criteria, we have tried to select studies with common characteristics. Therefore, direct comparisons between studies, especially with regard to absolute changes in BP, should not be made. However, in our Gourlay (64) Siklgy (65) Takabatake (66) Verdecchia (67) Whelton (68) (lmboni (69) De Cesaris (70) Gourlay (64) Graettinger (3) Herpin (71) Mann (60) Wheltcm (72) Whelton (68) Zachmiah (73 opinion, trough /peak ratios can be compared because these ratios represent relative values that are independent of study design and dosage as patients act as their own controls. Trough /peak ratios may be overestimated if patients do not respond to treatment, as the curve representing BP changes would flatten and approach zero. Individual data were not available for each patient; therefore, only mean values could be analyzed. Furthermore, it was not possible to calculate the standard deviations around the mean value. This may have introduced bias into our analysis, because the time to peak effect may differ between patients. Thus, the mean peak effect may have been underestimated, leading to an overestimation of trough /peak ratios. Another limitation, which must be acknowledged, is that the guidelines proposed by the FDA were based on casual assessment of BP in the clinic, rather than on ABPM.* Zanchetti and colleagues have discussed extensively the advantages and disadvantages of using ABPM to calculate this ratio and have considered various calculation methods.81They emphasized that calculating group ratios from individual ratios is fraught with problems. For instance individual ratios may not be normally distributed.49However, this author and coworkers have used several methods of calculations of the trough/ peak ratios of nifedipine GITS 30 and 60 mg and found that medians of the individual ratios were quite similar to the group ratios and remarkably consistent whatever the calculation method, despite the differences and potential limitations of the various methods.49 However, it is required that trough/peak ratios should be calculated from BP results that have been placebo-corrected.* Our criteria required a 2-week washout period, and in all studies patients received placebo during this washout period. Therefore, our trough/peak ratios were calculated from BP results that have been placebo-corrected.
Finally, only studies using ABPM were included in our analysis of the literature. Studies in which the BP was assessed by casual BP monitoring may provide results that are different from those presented here. For instance, despite only selecting studies that met rigid inclusion criteria, there were important differences between studies in the trough/peak ratio calculated for any given agent. The ratio calculated in studies varied more than two-fold for cilazapril, lisinopril, and quinapril as well as for many calcium antagonists. Many reasons may account for the variability between study results. Among these and specifically for slow-release calcium antagonists, variations in the slow-release formulations from one study to another may be an important contributing factor. In any case, the presence of such variability does support the need for further direct comparative prospective assessment. Additionally, some findings contrast with those based on alternative methodology such as in the case of perindopri116and the trough /peak ratios of ACE inhibitors approved by the FDA following the formulation of their new guidelines are higher than those reported in the studies analyzed in this review. For example, the trough/peak ratio is reported to be approximately 50% for benazepril (compared with 10% to 40% in our analysis), 50% for quinapril (compared with 30% to 40% in our analysis) and 50Y0to 60Y0for ramipril (compared with 40Y0to 50% in our analysis) (Physicians Desk Reference 1993) . In other respects, in the majority, not to say in all the studies that we have analyzed, results were reported as mean changes observed in the whole groups of patients with no division into "responders" and "nonresponders". This may have led to a dilution bias consequently underestimating the magnitude of mean BP changes, which, if any, should overestimate the calculated trough /peak ratio.
Clinical Implications There are many clinicalimplications associated with a stable BP reduction with a "smooth" time-effectprofile. Reducing the night-time BP as well as the daytime levels may be useful. It is well known that BP is subjectto a marked decrease at night, but even so, it remains higher in hypertensive than in normotensive subjects.17 The importance of night-time BP in determining hypertension-related cardiovascular complications was reported by several investigators.lsflgThis emphasizes the necessity of achieving good BP control during sleep to prevent the adverse influence of night-time hypertension on target organs. In other respects, a characteristic pattern of 24-h BP is the sharp early morning increase in BP, which may originate before awakening and which continues through to the midmorning hours. These morning BP changes probably reflect the parallel increase in the sympathetic nervous system activity that is associated ZIJ The rapid and pronounced with the arousal process. early morning rise in BP could account for the higher incidence of ischemic stroke and myocardial infarction reported at this time of day.21-24Even though the relationship between the morning rise in BP and the occurrence of cardiovascular events is still under investigation, the achievement of therapeutic control of BP during this period of high vulnerability might be a key property of antihypertensive therapy directed at preventing cardiovascular events. Obviously this can only be achieved by long-acting agents. This was probably one of the reasons that led experts from the FDA to state that: "In the controlled studies where the treatment of hypertension was associated with a decrease in mortality and /or stroke, the treatment regimen used probably retained most of their peak effects at their interdosing intervals (troughs). The Division has presumed that a similar time-effect relationship should be evinced by any new agent in order to increase the likelihood of clinical benefit to the patient."1 Finally, one of the major challenges in therapy is to maintain patient adherence to the treatment regimen on a long-term basis. Because hypertension is an asymptomatic condition, compliance with treatment requires strong motivation cm the patient's part. Moreover, treatment should be simple and convenient, and there hasbeena growinginterestby physiciansin using dregs that are effective when administered just once daily. C)bviously, despite the enthusiasm of patients and physicians for drugs with recommended once daily regimen, there are concerns that some uf these agents may not provide adequate BP contiol throughout the full 24-h day.''''-" Furthermore, the patient who is a poor complier is likely to quickly lose effective therapeutic ccwerage if a single dose of a short acting agent is occasionally omitted or delayed but not if a single dose of a long-acting drug is omitted or delayed.4y'78 1.
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